Cargando…
PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms
Spontaneously hypertensive rat (SHR) is a suitable model for studies of the complications of hypertension. It is known that activation of poly(ADP-ribose) polymerase enzyme (PARP) plays an important role in the development of postinfarction as well as long-term hypertension induced heart failure. In...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094529/ https://www.ncbi.nlm.nih.gov/pubmed/25014216 http://dx.doi.org/10.1371/journal.pone.0102148 |
_version_ | 1782325846922493952 |
---|---|
author | Deres, Laszlo Bartha, Eva Palfi, Anita Eros, Krisztian Riba, Adam Lantos, Janos Kalai, Tamas Hideg, Kalman Sumegi, Balazs Gallyas, Ferenc Toth, Kalman Halmosi, Robert |
author_facet | Deres, Laszlo Bartha, Eva Palfi, Anita Eros, Krisztian Riba, Adam Lantos, Janos Kalai, Tamas Hideg, Kalman Sumegi, Balazs Gallyas, Ferenc Toth, Kalman Halmosi, Robert |
author_sort | Deres, Laszlo |
collection | PubMed |
description | Spontaneously hypertensive rat (SHR) is a suitable model for studies of the complications of hypertension. It is known that activation of poly(ADP-ribose) polymerase enzyme (PARP) plays an important role in the development of postinfarction as well as long-term hypertension induced heart failure. In this study, we examined whether PARP-inhibitor (L-2286) treatment could prevent the development of hypertensive cardiopathy in SHRs. 6-week-old SHR animals were treated with L-2286 (SHR-L group) or placebo (SHR-C group) for 24 weeks. Wistar-Kyoto rats were used as aged-matched, normotensive controls (WKY group). Echocardiography was performed, brain-derived natriuretic peptide (BNP) activity and blood pressure were determined at the end of the study. We detected the extent of fibrotic areas. The amount of heat-shock proteins (Hsps) and the phosphorylation state of Akt-1(Ser473), glycogen synthase kinase (GSK)-3β(Ser9), forkhead transcription factor (FKHR)(Ser256), mitogen activated protein kinases (MAPKs), and protein kinase C (PKC) isoenzymes were monitored. The elevated blood pressure in SHRs was not influenced by PARP-inhibitor treatment. Systolic left ventricular function and BNP activity did not differ among the three groups. L-2286 treatment decreased the marked left ventricular (LV) hypertrophy which was developed in SHRs. Interstitial collagen deposition was also decreased by L-2286 treatment. The phosphorylation of extracellular signal-regulated kinase (ERK)1/2(Thr183-Tyr185), Akt-1(Ser473), GSK-3β(Ser9), FKHR(Ser256), and PKC ε(Ser729) and the level of Hsp90 were increased, while the activity of PKC α/βII(Thr638/641), ζ/λ(410/403) were mitigated by L-2286 administration. We could detect signs of LV hypertrophy without congestive heart failure in SHR groups. This alteration was prevented by PARP inhibition. Our results suggest that PARP-inhibitor treatment has protective effect already in the early stage of hypertensive myocardial remodeling. |
format | Online Article Text |
id | pubmed-4094529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-40945292014-07-15 PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms Deres, Laszlo Bartha, Eva Palfi, Anita Eros, Krisztian Riba, Adam Lantos, Janos Kalai, Tamas Hideg, Kalman Sumegi, Balazs Gallyas, Ferenc Toth, Kalman Halmosi, Robert PLoS One Research Article Spontaneously hypertensive rat (SHR) is a suitable model for studies of the complications of hypertension. It is known that activation of poly(ADP-ribose) polymerase enzyme (PARP) plays an important role in the development of postinfarction as well as long-term hypertension induced heart failure. In this study, we examined whether PARP-inhibitor (L-2286) treatment could prevent the development of hypertensive cardiopathy in SHRs. 6-week-old SHR animals were treated with L-2286 (SHR-L group) or placebo (SHR-C group) for 24 weeks. Wistar-Kyoto rats were used as aged-matched, normotensive controls (WKY group). Echocardiography was performed, brain-derived natriuretic peptide (BNP) activity and blood pressure were determined at the end of the study. We detected the extent of fibrotic areas. The amount of heat-shock proteins (Hsps) and the phosphorylation state of Akt-1(Ser473), glycogen synthase kinase (GSK)-3β(Ser9), forkhead transcription factor (FKHR)(Ser256), mitogen activated protein kinases (MAPKs), and protein kinase C (PKC) isoenzymes were monitored. The elevated blood pressure in SHRs was not influenced by PARP-inhibitor treatment. Systolic left ventricular function and BNP activity did not differ among the three groups. L-2286 treatment decreased the marked left ventricular (LV) hypertrophy which was developed in SHRs. Interstitial collagen deposition was also decreased by L-2286 treatment. The phosphorylation of extracellular signal-regulated kinase (ERK)1/2(Thr183-Tyr185), Akt-1(Ser473), GSK-3β(Ser9), FKHR(Ser256), and PKC ε(Ser729) and the level of Hsp90 were increased, while the activity of PKC α/βII(Thr638/641), ζ/λ(410/403) were mitigated by L-2286 administration. We could detect signs of LV hypertrophy without congestive heart failure in SHR groups. This alteration was prevented by PARP inhibition. Our results suggest that PARP-inhibitor treatment has protective effect already in the early stage of hypertensive myocardial remodeling. Public Library of Science 2014-07-11 /pmc/articles/PMC4094529/ /pubmed/25014216 http://dx.doi.org/10.1371/journal.pone.0102148 Text en © 2014 Deres et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Deres, Laszlo Bartha, Eva Palfi, Anita Eros, Krisztian Riba, Adam Lantos, Janos Kalai, Tamas Hideg, Kalman Sumegi, Balazs Gallyas, Ferenc Toth, Kalman Halmosi, Robert PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms |
title | PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms |
title_full | PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms |
title_fullStr | PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms |
title_full_unstemmed | PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms |
title_short | PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms |
title_sort | parp-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, akt-1/gsk-3β and several pkc isoforms |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094529/ https://www.ncbi.nlm.nih.gov/pubmed/25014216 http://dx.doi.org/10.1371/journal.pone.0102148 |
work_keys_str_mv | AT dereslaszlo parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms AT barthaeva parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms AT palfianita parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms AT eroskrisztian parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms AT ribaadam parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms AT lantosjanos parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms AT kalaitamas parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms AT hidegkalman parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms AT sumegibalazs parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms AT gallyasferenc parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms AT tothkalman parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms AT halmosirobert parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms |